Download Poster (639 KB)
The purpose of this study is to review the efficacy of Target Specific Oral Anticoagulants (TSOAC) versus vitamin K antagonist (VKA) for post-surgical anticoagulation in patient with primary subclavian vein thrombosis. Rivaroxaban, a factor Xa inhibitor, was the first TSOAC approved by the FDA in 2012 for the treatment and prevention of deep vein thrombosis. However, the efficacy and safety of TSOAC for prevention of recurrent deep vein thrombosis after revascularization of upper extremity compression syndromes is largely unknown.
Role of Target Specific Oral Anticoagulation After Operative Management of Venous Thoracic Outlet Syndrome, Thomas Jefferson University, poster
Kwon, MD, Jeontaik; DiMuzio, MD, Paul J.; Abai, MD, Babak; Salvatore, MD, Dawn; Galanis, MD, Taki; Merli, MD, Geno J.; and Eraso, MD, Luis H., "Role of Target Specific Oral Anticoagulation After Operative Management of Venous Thoracic Outlet Syndrome" (2016). Department of Surgery Posters. 2.